Brought to you by The Marketing GP, TROG Cancer Research, and Peaberrys Coffee Roasters
Well-respected not-for-profit, TROG Cancer Research, is at the centre of a collaboration between a marketing agency and coffee roaster, with a signature coffee blend created for a good cause.
As part of their 10-year anniversary celebration and occurring at the same time as the business overhauled its brand, The Marketing GP has created The NewyWay Blend in collaboration with Peaberrys Coffee Roasters.
Carefully selected and roasted to represent the community they share, a percentage of proceeds from every purchase of coffee will support vital research to help improve outcomes and the quality of life of cancer patients for generations.
TROG Cancer Research operates off a collaborative group clinical trial model and is this year celebrating the recruitment of their 15,000th trial participant. This achievement comes after 30 years of trial development and conduct, helping to provide better outcomes for those affected by cancer in Australia and globally.
Chief Marketer and Managing Director of The Marketing GP, Holly Martin said it felt only natural to give back to a community that has given the business, their team, and clients so much. And what better way than with a good cup of joe!
“Everyone has their own ritualistic way of starting the day. For many, this includes a good cup of coffee. We wanted to create a coffee blend with a local roaster that does good for our community and supporting the vital work of an organisation that was grown in Newcastle, but makes an impact nationally and globally, was a natural fit.
“Through our work, we get the amazing opportunity to meet and collaborate with a lot of people. This coffee blend is a result of those connections and the great community who’ve always had our backs,” Holly said.
TROG Cancer Research CEO, Susan Goode said when Holly reached out to be a charity partner, they were blown away by the generosity.
“We’ve had the pleasure of knowing and working with The Marketing GP professionally for a few years now, and it’s wonderful to collaborate for a greater cause and celebrate our big wins together.
“Sadly, one way or another, most people have been exposed to the devastating impact of cancer. Our team are dedicated to outsmarting cancer and finding better treatments, so patients can live a life beyond cancer and spend more time with their loved ones.
The coffee blend will support TROG Cancer Research, which has its headquarters in Newcastle but works collaboratively with innovative minds around the world to find breakthroughs in cancer treatments using radiation therapy.
“This opportunity presented by The Marketing GP allows us to share our message and continue conducting life-changing research and trials around the world from our headquarters right here in Newcastle,” Susan said.
Peaberrys Coffee Roasters Owner, Adrian Rigon said The NewyWay Blend brings together all the wonderful elements of being a Novocastrian (the nickname for locals of Newcastle) into your daily cup of coffee.
“We’ve sought coffee beans from Brazil, Ethiopia, and Papua New Guinea – keeping quality at the core of this blend.
“Working alongside The Marketing GP team, we tested and tweaked the coffee with care to roast a delicious blend that could be enjoyed black or with your favourite milk product. We hope people enjoy each sip knowing they are contributing to something very special and enjoying a coffee that has been made with a lot of love,” Adrian said.
The Marketing GP team is gratified to now share cups of coffee with the community and launch this passion project, which has been a work in progress for many months.
“We look forward to seeing people show their support and drink some quality coffee while helping TROG Cancer Research continue providing improved radiation treatments to cancer patients locally and internationally,” Holly shared.
You can purchase a 250g bag of The NewyWay Blend coffee beans for $17 or a 1kg bag of coffee beans for $57 online here now. A percentage of all purchases will be donated to TROG Cancer Research.